Antigenicity Identification of a Novel Recombinant Multi-Epitope Antigen Based on FlaA and UreB Antigens of Helicobacter pylori

Hamzehloo, Zeinab; Mosayebi, Ghasem; Khansarinejad, Behzad; Zolfaghari, Mina; Abtahi, Hamid

doi:10.5812/jjm.66502

Cited by 3 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The induction result was confirmed by transferring the resulting protein to the (12%) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. Finally, the extraction of synthesized recombinant protein was performed by using Ni-NTA kit (Qiagen, USA), according to the manufacturer's instructions (14,15).…”

Section: Cloning Expression and Purification Of Recombinant Protein mentioning

confidence: 99%

Recombinant Oncorhyncin II Effect on the Treatment of Methicillin-Resistant Staphylococcus aureus Skin Infection

Jafari

Ghaznavi‐Rad

Fahimirad

2020

Jundishapur J Microbiol

Self Cite

View full text Add to dashboard Cite

Background: Methicillin-resistant Staphylococcus aureus (MRSA) is known to be one of the most potentially pathogenic organisms in the world. Skin infections are one of the significant infections of S. aureus. Therefore, therapeutic constraints have challenged researchers to seek new strategies to produce new medicines. Antimicrobial peptides (AMPs) are a new generation of natural drugs with antimicrobial properties and high fatality potency. Oncorhyncin II AMP is a group of peptides with bacteriostatic activity and antimicrobial effect against Gram-positive and Gram-negative bacteria. Therefore, the development and promotion of antimicrobial peptides can be a new step in the treatment of skin infections due to bacterial resistant S. aureus in hospitals. Objectives: The objective of this study was to produce recombinant Oncorhyncin II protein and evaluate its antimicrobial effects on MRSA to determine the outcomes of the treatment. Methods: In this experimental study, the Oncorhyncin II Antimicrobial peptide was synthesized by the recombinant method. The effectiveness of this peptide was assessed by the minimum inhibitory concentration (MIC) test. The activity of recombinant protein against S. aureus was investigated using in vitro and in vivo experiments. Results: The effectiveness of this peptide obtained by the MIC test was 225 µg/mL. The activity test confirmed the MIC test and showed that this antimicrobial peptide has been able to reduce MRSA cell growth. All mice infected with MRSA responded positively to the protein treatment. Conclusions: According to Oncorhyncin II antimicrobial peptide activity studies, this peptide, as a new generation of antibiotics, was expected to have positive outcomes in the improvement of S. aureus skin infections. Therefore, the results of the efficacy require further studies to be confirmed.

show abstract

Section: Cloning Expression and Purification Of Recombinant Protein mentioning

confidence: 99%

Recombinant Oncorhyncin II Effect on the Treatment of Methicillin-Resistant Staphylococcus aureus Skin Infection

Jafari

Ghaznavi‐Rad

Fahimirad

2020

Jundishapur J Microbiol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Epitope-based vaccines are more cost-effective than mixed proteins and can cover more protein targets, so multiepitope vaccines receive more attention. 91 …”

Section: Discussionmentioning

confidence: 99%

“…The recombinant protein can be recognized in the sera of patients with H. pylori infection with high sensitivity and specificity. 91 …”

Section: Antigensmentioning

confidence: 99%

“…Epitope-based vaccines are more cost-effective than mixed proteins and can cover more protein targets, so multiepitope vaccines receive more attention. 91 Clinical studies have proved that most of the adverse reactions in tested populations are caused by adjuvants, 15,21 so it is necessary to explore an a toxic or low-toxicicty but effective adjuvant. Aluminum hydroxide and LT are widely used adjuvants of H. pylori vaccine in clinical research, but aluminum hydroxide does not enhance cellular immunity.…”

Section: Improvement Of Vaccine-design Strategymentioning

confidence: 99%

See 1 more Smart Citation

How Long Will It Take to Launch an Effective Helicobacter pylori Vaccine for Humans?

Li¹,

Zhao²,

Xia³

et al. 2023

IDR

View full text Add to dashboard Cite

Helicobacter pylori infection often occurs in early childhood, and can last a lifetime if not treated with medication. H. pylori infection can also cause a variety of stomach diseases, which can only be treated with a combination of antibiotics. Combinations of antibiotics can cure H. pylori infection, but it is easy to relapse and develop drug resistance. Therefore, a vaccine is a promising strategy for prevention and therapy for the infection of H. pylori . After decades of research and development, there has been no appearance of any H. pylori vaccine reaching the market, unfortunately. This review summarizes the aspects of candidate antigens, immunoadjuvants, and delivery systems in the long journey of H. pylori vaccine research, and also introduces some clinical trials that have displayed encouraging or depressing results. Possible reasons for the inability of an H. pylori vaccine to be available over the counter are cautiously discussed and some propositions for the future of H. pylori vaccines are outlined.

show abstract

“…UreB has been detected in the bacteria cytoplasm and periplasm (Marcus et al 2013 ), but also on the bacteria surface (Haas et al 2000). Flagellin A (FlaA) is a motility factor, involved in the colonization of the host and on the inflammatory processes (Gu et al 2017 ) and has been suggested as a good vaccine target (Yan et al 2003 ; Hamzehloo et al 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Antigenic and conserved peptides from diverse Helicobacter pylori antigens

Calado

2022

Biotechnol Lett

View full text Add to dashboard Cite

Since the revolutionary finding of Helicobacter pylori as a common bacterial infection, that a high research effort for its eradication has been conducted. Epitope based-vaccine presents advantages over protein-based, as they can be designed to contain epitopes from diverse proteins, therefore, more easily representing the immune-variability of the bacterial population, while minimizing the toxicity associated to some whole proteins. In the present work, an iterative method, to design antigenic and conserved B-epitopes from diverse virulent factors of H. pylori, was established. The method considered the trade-off between epitopes antigenicity and conservation among the bacterial population. For the method validation, five virulent factors from H. pylori were selected. From each virulent factor, two epitopes were predicted, each with twelve residues of aminoacids. The corresponding ten peptides were synthesised and evaluated by enzyme-linked immunosorbent assay using polyclonal antibodies raised against a specific H. pylori strain. All ten peptides were recognised by the antibodies and were consequently antigenic and conserved. This result could strongly contribute to the design of a multivalent epitope-based vaccine, representing the immunogenetic variability within the bacterial population, leading to a sustained and effective immunogenic protection.

show abstract

Antigenicity Identification of a Novel Recombinant Multi-Epitope Antigen Based on FlaA and UreB Antigens of Helicobacter pylori

Cited by 3 publications

References 44 publications

Recombinant Oncorhyncin II Effect on the Treatment of Methicillin-Resistant Staphylococcus aureus Skin Infection

Recombinant Oncorhyncin II Effect on the Treatment of Methicillin-Resistant Staphylococcus aureus Skin Infection

How Long Will It Take to Launch an Effective Helicobacter pylori Vaccine for Humans?

Antigenic and conserved peptides from diverse Helicobacter pylori antigens

Contact Info

Product

Resources

About